| The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients C Camps, E Jantus-Lewintre, A Cabrera, A Blasco, E Sanmartín, ... Lung Cancer 72 (3), 365-369, 2011 | 69 | 2011 |
| Management of malignant insulinoma JC Ferrer-García, V Iranzo González-Cruz, S Navas-DeSolís, ... Clinical and Translational Oncology 15, 725-731, 2013 | 42 | 2013 |
| Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG … MÁ Climent, B Pérez-Valderrama, B Mellado, EMF Parra, OF Calvo, ... European Journal of Cancer 87, 30-37, 2017 | 27 | 2017 |
| Toxicidad de los tratamientos oncológicos A Blasco, C Caballero SEOM Sociedad Española de Oncología Médica [Internet], 2019 | 24 | 2019 |
| Analysis of the Prognostic Value of Soluble Epidermal Growth Factor Receptor Plasma Concentration in Advanced Non–Small-Cell Lung Cancer Patients E Jantus-Lewintre, R Sirera, A Cabrera, A Blasco, C Caballero, V Iranzo, ... Clinical lung cancer 12 (5), 320-327, 2011 | 24 | 2011 |
| SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018) A González del Alba, G De Velasco, N Lainez, P Maroto, ... Clinical and Translational Oncology 21, 64-74, 2019 | 23 | 2019 |
| Solitary thoracic intradural extramedullary plasmacytoma I Zazpe, C Caballero, T Cabada, D Guerrero, A Gallo-Ruiz, E Portillo Acta Neurochirurgica 149, 529-532, 2007 | 23 | 2007 |
| Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer C Camps, R Sirera, RM Bremnes, V Ródenas, A Blasco, MJ Safont, ... Anticancer research 26 (6C), 4905-4909, 2006 | 19 | 2006 |
| Chemotherapy-Induced Neutropenia Does Not Correlate With DNA Repair Gene Polymorphisms and Treatment Efficacy in Advanced Non–Small-Cell Lung Cancer Patients V Iranzo, R Sirera, RM Bremnes, A Blasco, E Jantus-Lewintre, M Tarón, ... Clinical lung cancer 12 (4), 224-230, 2011 | 18 | 2011 |
| The prognostic value of hTERT expression levels in advanced-stage colorectal cancer patients: a comparison between tissue and serum expression MJ Safont, M Gil, R Sirera, E Jantus-Lewintre, E Sanmartín, S Gallach, ... Clinical and Translational Oncology 13, 396-400, 2011 | 16 | 2011 |
| ESTUDIO DESCRIPTIVO SOBRE EL RECUERDO DEL PACIENTE TRAS LA COMUNICACIÓN DEL DIAGNÓSTICO Y DEL PRONÓSTICO EN ONCOLOGÍA. ML Vidal, PT Sánchez, C Corbellas, G Peiró, M Godes, A Blasco, ... Psicooncología 4 (1), 2007 | 15 | 2007 |
| A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study. A Oaknin, A Gonzalez-Martin, Y García, S Catot, C Caballero, ... Journal of Clinical Oncology 30 (15_suppl), 5068-5068, 2012 | 14 | 2012 |
| Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists C Camps-Herrero, L Paz-Ares, M Codes, R López-López, A Antón-Torres, ... Clinical and Translational Oncology 16, 914-920, 2014 | 12 | 2014 |
| Deterioro cognitivo asociado al tratamiento oncológico A Blasco, C Caballero, C Camps CM de Psicobioquímica 2, 26-36, 2013 | 12 | 2013 |
| Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability C Camps, C Caballero, A Blasco, MJ Safont, A Berrocal, J Garde, ... Anticancer research 25 (6C), 4611-4614, 2005 | 12 | 2005 |
| Can the Spanish care system assume the new costs of medications against cancer? C Camps, C Caballero, R Sirera, A Blasco, D Cayuela, M Gil, X Badía Clinical and Translational Oncology 10, 96-101, 2008 | 11 | 2008 |
| SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021) BP Valderrama, A González-del-Alba, R Morales-Barrera, ... Clinical and Translational Oncology 24 (4), 613-624, 2022 | 10 | 2022 |
| Niveles séricos de il-6 y depresión en varones con cáncer de pulmón no microcítico avanzado JM Sánchez, PT Sanchez, G Peiró, R Sirera, M De Lamo, C Corbellas, ... CM de Psicobioquimica 2, 53-62, 2013 | 7 | 2013 |
| Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels. M Joerger, BC Cho, N Mach, C Caballero, RA Soo, M Wirth, C Sayehli, ... Journal of Clinical Oncology 37 (15_suppl), e20661-e20661, 2019 | 6 | 2019 |
| Intracranial hemorrhage from an arteriovenous malformation (AVM) in a tuberous sclerosis patient J Guridi, M Tuñón, C Caballero, A Gallo-Ruiz, A Vázquez, I Zazpe Neurologia (Barcelona, Spain) 16 (6), 281-284, 2001 | 6 | 2001 |
